Patents by Inventor Volker Erfle
Volker Erfle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8197825Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: GrantFiled: June 14, 2010Date of Patent: June 12, 2012Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Patent number: 8153138Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: GrantFiled: September 19, 2006Date of Patent: April 10, 2012Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Publication number: 20110293656Abstract: The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA.Type: ApplicationFiled: May 18, 2011Publication date: December 1, 2011Inventors: Gerd Sutter, Volker Erfle, Caroline Staib, Yuan Wang, Guangdi Li, Li-Xin Zhu
-
Publication number: 20110236409Abstract: The present invention relates to set overlapping immunogenic peptides of a variable antigen, and uses thereof, in particular for diagnostic and therapeutic purposes. The present invention relates also to a sub-population of CD8 T cells associated with the non-progressive status in HIV-infected subjects.Type: ApplicationFiled: March 30, 2009Publication date: September 29, 2011Applicant: Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Mauro Severo Malnati, Paolo Lusso, Guido Poli, Antonio Cosma, Volker Erfle
-
Publication number: 20100291139Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: ApplicationFiled: June 14, 2010Publication date: November 18, 2010Inventors: GERD SUTTER, Marion Ohlmann, Volker Erfle
-
Publication number: 20100266630Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: ApplicationFiled: September 19, 2006Publication date: October 21, 2010Applicant: GSF-Forschungszentrum Fur Umwelt und Gesundheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Patent number: 7767209Abstract: The present invention is directed to a MVA mutant and its use in the immunotherapy and vaccination against numerous diseases, in particular in the prevention and therapy of cancer and infectious diseases.Type: GrantFiled: March 14, 2006Date of Patent: August 3, 2010Assignee: GSF-Forschungszentrum fuer Umwelt und Gesundheit GmbHInventors: Caroline Staib, Gerd Sutter, Sigried Kiesling, Volker Erfle
-
Publication number: 20090238843Abstract: The invention relates to recombinant MVA which is capable of expressing structural HCV antigens, functional parts of said structural antigens or epitopes of said structural antigens. The invention further relates to a pharmaceutical composition, especially in the form of a vaccine and containing the recombinant MVA according to the invention, to eukaryotic cells that contain the inventive recombinant MVA and to various uses of the recombinant MVA, for example for producing recombinant structural proteins, for producing a pharmaceutical preparation that is suitable for the therapy and prophylaxis of HCV infections and diseases thereby caused. The invention further relates to methods for producing recombinant MVA and recombinant structural HCV polypeptides encoded by said recombinant MVA, and to DNA or RNA of said recombinant MVA.Type: ApplicationFiled: June 2, 2009Publication date: September 24, 2009Inventors: Gerd Sutter, Volker Erfle, Caroline Staib, Yuan Wang, Guangdi Li, Li-Xin Zhu
-
Publication number: 20080075694Abstract: The present invention is directed to a recombinant MVA, which carries a nucleic acid sequence coding for a fusion protein. The present invention is further directed to a kit of parts containing said recombinant MVA as well as to a method for enhancing T cell responses in a mammal.Type: ApplicationFiled: July 19, 2007Publication date: March 27, 2008Inventors: Ingo Drexler, Gerd Sutter, Georg Gasteiger, Volker Erfle
-
Publication number: 20070160627Abstract: The present invention is directed to a MVA mutant and its use in the immunotherapy and vaccination against numerous diseases, in particular in the prevention and therapy of cancer and infectious diseases.Type: ApplicationFiled: March 14, 2006Publication date: July 12, 2007Inventors: Caroline Staib, Gerd Sutter, Sigried Kiesling, Volker Erfle
-
Patent number: 7198934Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: GrantFiled: May 15, 2002Date of Patent: April 3, 2007Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Publication number: 20070071769Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: ApplicationFiled: September 19, 2006Publication date: March 29, 2007Applicant: GSF-Forschungszentrum Fur Umwelt und Gesundheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Publication number: 20070071770Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: ApplicationFiled: September 19, 2006Publication date: March 29, 2007Applicant: GSF-Forschungszentrum Fur Umwelt und Gesundheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Patent number: 7183047Abstract: The present invention relates to a reporter gene construct for the detection of the HIV Rev and HIV Tat proteins. Furthermore, the invention relates to a functionality test method for Rev and Rev fusion proteins prepared in a recombinant manner, a method of screening for sequences of different origin for their activity as an instability element, a method of screening for sequences which cause the transport out of the nucleus into the cytoplasm by binding to cellular or other viral shuttle proteins, as well as to a method for the detection of HIV-infected cells. The reporter gene construct according to the present invention, after it has been introduced into cells, in the presence of HIV Rev and HIV Tat proteins results in the formation of reporter proteins which may be used for quantitative/qualitative detection of the HIV Rev and HIV Tat proteins.Type: GrantFiled: June 20, 2002Date of Patent: February 27, 2007Assignee: GSF-Forschungszentrum für Umwelt und Gesundheit, GmbHInventors: Ruth Brack-Werner, Markus Neumann, Horst Wolff, Volker Erfle
-
Patent number: 7150874Abstract: A new DNA vector is disclosed comprising a nucleic acid sequence useful for inserting heterologous sequences into the genome of poxviruses by homologous recombination. Also disclosed are recombinant poxviruses carrying heterologous coding sequences transferred by the DNA vector.Type: GrantFiled: September 23, 2003Date of Patent: December 19, 2006Assignee: GFS Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Stefan Wintersperger, Robert Baier, Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Patent number: 7049145Abstract: The present invention relates to mutant MVA vaccinia viruses, which are used for the generation of recombinant MVA viruses, as well as host cells, which have been infected with these mutant MVA viruses. The present invention further relates to DNA-vector constructs, and a method for the generation of recombinant MVA by using the mutant MVA viruses and the DNA-vector constructs. The mutant MVA vaccinia viruses of the present invention are characterized in that the MVA ORF 050L gene or a functional part thereof has been inactivated in the viral genome.Type: GrantFiled: September 11, 2002Date of Patent: May 23, 2006Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit, GmbHInventors: Volker Erfle, Simone Hornemann, Gerd Sutter
-
Publication number: 20060002896Abstract: The present invention relates to MVA mutants, which can be used for the generation of recombinant MVA viruses, as well as host cells, which have been infected with these mutant MVA viruses. The present invention further relates to DNA-vector constructs, and a method for the generation of recombinant MVA by using the mutant MVA viruses and the DNA-vector constructs.Type: ApplicationFiled: June 10, 2005Publication date: January 5, 2006Inventors: Caroline Staib, Marianne Loewel, Volker Erfle, Gerd Sutter
-
Publication number: 20050287162Abstract: The invention relates to a recombinant fowlpox virus (FWPV) and a DNA vector containing gene sequences for one such recombinant fowlpox virus. The invention also relates to a pharmaceutical composition containing said recombinant fowlpox virus or a DNA vector, to the use of said recombinant fowlpox virus for treating infectious diseases or tumour diseases, and to a method for producing said recombinant fowlpox virus or DNA vector. The invention further relates to eukaryote cells or prokaryote cells containing the recombinant DNA vector or the recombinant fowlpox virus. The invention is based on the identification of the FWPV-F11L gene as a novel insertion site for foreign DNA.Type: ApplicationFiled: May 13, 2003Publication date: December 29, 2005Inventors: Robert Baier, Denise Boulanger, Volker Erfle, Gerd Sutter
-
Patent number: 6869793Abstract: Recombinant MVA viruses containing and/or capable of expressing dengue virus antigens and the use of such recombinant MVA for vaccination.Type: GrantFiled: September 23, 1997Date of Patent: March 22, 2005Assignee: Bavarian Nordic Research InstituteInventors: Mary Jane Cardosa, Gerd Sutter, Volker Erfle
-
Publication number: 20050028226Abstract: The present invention relates to mutant MVA vaccinia viruses, which are used for the generation of recombinant MVA viruses, as well as host cells, which have been infected with these mutant MVA viruses. The present invention further relates to DNA-vector constructs, and a method for the generation of recombinant MVA by using the mutant MVA viruses and the DNA-vector constructs. The mutant MVA vaccinia viruses of the present invention are characterized in that the MVA ORF 050L gene or a functional part thereof has been inactivated in the viral genome.Type: ApplicationFiled: September 11, 2002Publication date: February 3, 2005Inventors: Volker Erfle, Simone Hornemann, Gerd Sutter